Laura Q M Chow

5PUBLICATIONS
36CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsiesPredictive and prognostic markersMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.

Tae Won Kim, Howard A Burris, Maria J de Miguel Luken

|Jun 13, 2022
Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.

Laura C Kennedy, Jun Lu, Sydney Kuehn

|Jan 29, 2022
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.

Laura Q M Chow, Fabrice Barlesi, Erin M Bertino

|Jun 10, 2021
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.

Edward B Garon, Alexander I Spira, Melissa Johnson

|Jan 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Hossein Borghaei, Scott Gettinger, Everett E Vokes

Pageof 1

Frequent Collaborators

1 joint publications

Tae Won Kim

1 joint publications

Maria J de Miguel Luken

1 joint publications

Michael J Pishvaian

1 joint publications

Yung-Jue Bang